Biomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)

Saad, F.Armstrong, A. J.Thiery-Vuillemin, A.Oya, M.Shore, N. D.Procopio, G.Arslan, C.2023-06-162023-06-1620220923-75341569-8041https://hdl.handle.net/20.500.14365/3235Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessBiomarker Analysis and Updated Results From the Phase Iii Propel Trial of Abiraterone (abi) and Olaparib (ola) Vs Abi and Placebo (pbo) as First-Line (1l) Therapy for Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mcrpc)Conference Object